Kane Biotech (TSX-V:KNE; OTCQB:KNIBF) received the U.S. DoD’s Medical Technology Enterprise Consortium (MTEC) Research Project Award for DispersinB.
The non-dilutive $2.7-million award will fund continued clinical development of DispersinB for the treatment of biofilm-mediated antimicrobial resistance in non-healing chronic wounds.
“We are thrilled to receive this MTEC award, which we believe is a testament and preliminary validation to both the DispersinB technology as well as the dire need for a non-healing chronic wound treatment,” Marc Edwards, CEO of Kane Biotech, said in a statement.
“This award is transformative for our human health business and will support our work to identify the product’s optimal development and regulatory approval path,” he added.
The company noted that wound care is the most expensive area of healthcare that relies on multiple, complex treatment modalities, rather than a single solution. The formation of bacterial biofilms, which are present in some 60% of chronic wounds, often leads to the failure of currently available chronic wound treatments.
